High Growth Tech Stocks in Australia Including FINEOS Corporation Holdings

Simply Wall St.
24 Apr

The Australian market has been experiencing a period of volatility, with recent developments such as Trump's decision to ease tariffs on China contributing to the ASX's movement back towards the 8,000-point mark. In this dynamic environment, high-growth tech stocks like FINEOS Corporation Holdings are attracting attention for their potential resilience and innovation-driven growth amid broader market fluctuations.

Top 10 High Growth Tech Companies In Australia

Name Revenue Growth Earnings Growth Growth Rating
Gratifii 42.14% 113.99% ★★★★★★
Pro Medicus 22.19% 23.49% ★★★★★★
WiseTech Global 20.37% 25.23% ★★★★★★
BlinkLab 65.54% 64.35% ★★★★★★
Wrkr 57.01% 116.83% ★★★★★★
AVA Risk Group 29.15% 108.15% ★★★★★★
Pointerra 50.42% 159.12% ★★★★★☆
Echo IQ 84.54% 87.08% ★★★★★★
SiteMinder 21.09% 65.36% ★★★★★★
Advanced Health Intelligence 166.58% 178.92% ★★★★★☆

Click here to see the full list of 48 stocks from our ASX High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

FINEOS Corporation Holdings

Simply Wall St Growth Rating: ★★★★☆☆

Overview: FINEOS Corporation Holdings plc develops and sells enterprise claims and policy management software for life, accident, and health insurers as well as employee benefits providers across North America, the Asia Pacific, the Middle East, and Africa with a market cap of A$656.72 million.

Operations: The company generates revenue primarily from its Software & Programming segment, amounting to €133.22 million. It focuses on providing solutions for claims and policy management tailored to life, accident, and health insurance sectors.

FINEOS Corporation Holdings, a leader in insurance software solutions, has recently announced strategic partnerships that underscore its commitment to modernizing the industry. By integrating with Wellthy and Sutherland, FINEOS aims to enhance efficiency and compliance across benefits management. These collaborations are set to streamline operations by leveraging AI-driven solutions and pre-built integrations, which reduce implementation costs and accelerate market readiness. The company's focus on expanding holistic care offerings aligns with growing market demands for comprehensive services beyond traditional insurance benefits. This strategy not only addresses immediate administrative challenges but also positions FINEOS at the forefront of innovation in a competitive landscape. With projected annual revenue growth of 5.7% and an anticipated shift into profitability within three years, these developments could significantly influence its financial trajectory.

  • Click here to discover the nuances of FINEOS Corporation Holdings with our detailed analytical health report.
  • Review our historical performance report to gain insights into FINEOS Corporation Holdings''s past performance.

ASX:FCL Revenue and Expenses Breakdown as at Apr 2025

Pro Medicus

Simply Wall St Growth Rating: ★★★★★★

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system software to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$21.80 billion.

Operations: The company generates revenue by producing integrated software applications for the healthcare industry, amounting to A$184.58 million.

Pro Medicus, a trailblazer in medical imaging software, showcases robust growth with a 22.2% annual revenue increase and an impressive 23.5% rise in earnings per year. Recently added to the S&P/ASX 50 Index, the company has committed to a significant share repurchase program, planning to buy back up to 10 million shares by March 2026. This move reflects strong financial health and confidence in sustained growth, underscored by their recent performance with half-year sales jumping from AUD 74.11 million to AUD 97.19 million—a testament to their expanding market presence and innovation-driven approach in healthcare technology.

  • Unlock comprehensive insights into our analysis of Pro Medicus stock in this health report.
  • Examine Pro Medicus' past performance report to understand how it has performed in the past.

ASX:PME Earnings and Revenue Growth as at Apr 2025

SEEK

Simply Wall St Growth Rating: ★★★★☆☆

Overview: SEEK Limited operates as an online employment marketplace service provider across Australia, South East Asia, New Zealand, the United Kingdom, Europe, and other international regions with a market capitalization of A$7.47 billion.

Operations: SEEK Limited generates revenue primarily from its Employment Marketplaces in ANZ, contributing A$821.40 million, and Asia, with A$240.90 million.

SEEK Limited, amidst a challenging Interactive Media and Services industry, has demonstrated resilience with a 9.2% forecasted annual revenue growth and an impressive 26.3% expected rise in earnings per year. Despite a substantial one-off loss of A$119.8 million last fiscal year, the firm's strategic focus on innovation is evident from its R&D commitment, aligning with broader industry trends towards digital transformation and enhanced data analytics capabilities in recruitment services. The recent decision to increase dividends by 26%, paired with robust half-year net income growth from AUD 29.8 million to AUD 143.5 million, underscores management's confidence in sustained profitability and shareholder value creation.

  • Click to explore a detailed breakdown of our findings in SEEK's health report.
  • Learn about SEEK's historical performance.

ASX:SEK Earnings and Revenue Growth as at Apr 2025

Next Steps

  • Reveal the 48 hidden gems among our ASX High Growth Tech and AI Stocks screener with a single click here.
  • Invested in any of these stocks? Simplify your portfolio management with Simply Wall St and stay ahead with our alerts for any critical updates on your stocks.
  • Simply Wall St is your key to unlocking global market trends, a free user-friendly app for forward-thinking investors.

Ready To Venture Into Other Investment Styles?

  • Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
  • Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
  • Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include ASX:FCL ASX:PME and ASX:SEK.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10